Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota compositionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether the composition of the intestinal microbiota is associated with treatment outcome in multiple myeloma (MM), specifically minimal residual disease (MRD) status after upfront treatment. Fecal samples were analyzed using 16S ribosomal RNA sequencing to characterize microbiota composition. Samples were collected after induction therapy and at the time of flow cytometry-based bone marrow MRD testing. The analysis also compared microbial relative abundance against autologous stem cell transplantation history and MM paraprotein isotype.
Who was studied?
The study included 34 patients with multiple myeloma who had undergone induction therapy. Of these, 16 patients were classified as MRD-negative and 18 as MRD-positive based on bone marrow flow cytometry testing. All participants provided fecal samples for microbiota analysis. No further demographic details are given in the abstract.
What were the most important findings?
MRD-negative patients showed a higher relative abundance of Eubacterium hallii compared with MRD-positive patients. No association was found between microbial relative abundance and either autologous stem cell transplantation history or MM paraprotein isotype. Additionally, no differences in microbiota alpha diversity were observed between the MRD-negative and MRD-positive groups. This suggests that specific taxa, rather than overall diversity, may relate to treatment response.
What are the greatest implications of this study?
The findings point to a potential link between intestinal microbiota composition, particularly Eubacterium hallii abundance, and achieving MRD negativity in multiple myeloma. Since MRD negativity is associated with superior outcomes, this raises the possibility that the gut microbiome could serve as a biomarker or modifiable factor in MM treatment response. The authors frame this as a preliminary association warranting further correlative and clinical investigation rather than a definitive causal finding. Larger studies would be needed to confirm and clarify this relationship.